Chronic respiratory conditions like Asthma, Interstitial lung disease (ILD) and Chronic obstructive pulmonary disease (COPD) are incurable, but can be treated and managed. However, in practice, these conditions are poorly managed because patients lack discipline, guidance, education, and the right tools to effectively participate in their treatment.
Briota is building SiA (Systematic Intervention Agent), an AI-First and IOT Enabled Personalised Digital Respiratory Therapeutics service for patients suffering from Asthma, COPD, and Lung Fibrosis. Briota’s SiA service provides critical access to accurate diagnoses, unique abilities to monitor treatment progress, and connect and share test results with your doctors instantaneously, empowering care teams to make better decisions.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
Briota is currently having established business operations in Denmark and India, where they are collaborating with partners, including, Mankind Pharma, the Government of India Health Department, and Aarhus University Hospital.
Briota’s leadership team includes highly experienced individuals from MedTech, AI, Healthcare, Insurance, and Pharma and are based in Denmark, India, and Japan.
Unique selling point
Briota is using clinically proven, innovative and scalable technology with a multidisciplinary, personalized, and holistic approach that is focused on the patient's involvement in controlling disease progression at home. Other available solutions address only some part of the puzzle.
Briota has a close collaboration with a Japanese business partner, Mr. Ken Yanaginouchi. They are looking to further strengthen their business activities in East Asia, where they are currently looking for funding.
GET IN TOUCH WITH